866-997-4948(US-Canada Toll Free)

Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 29 Pages

Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2017, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 5 and 3 respectively.

Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Progressive Multifocal Leukoencephalopathy - Overview 5
Progressive Multifocal Leukoencephalopathy - Therapeutics Development 6
Pipeline Overview 6
Pipeline by Companies 7
Products under Development by Companies 8
Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment 9
Assessment by Target 9
Assessment by Mechanism of Action 11
Assessment by Molecule Type 13
Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development 15
Excision BioTherapeutics Inc 15
Neurimmune Holding AG 15
Neuway Pharma GmbH 15
Pomona Ricerca SRL 16
Progressive Multifocal Leukoencephalopathy - Drug Profiles 17
EBT-103 - Drug Profile 17
Product Description 17
Mechanism Of Action 17
R&D Progress 17
IKT-01427 - Drug Profile 18
Product Description 18
Mechanism Of Action 18
R&D Progress 18
imatinib mesylate - Drug Profile 19
Product Description 19
Mechanism Of Action 19
R&D Progress 19
Monoclonal Antibody for JCV and PML Infections - Drug Profile 20
Product Description 20
Mechanism Of Action 20
R&D Progress 20
NI-307 - Drug Profile 21
Product Description 21
Mechanism Of Action 21
R&D Progress 21
NPW-007 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
PNJC-1 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
Progressive Multifocal Leukoencephalopathy - Dormant Projects 25
Progressive Multifocal Leukoencephalopathy - Product Development Milestones 26
Featured News & Press Releases 26
May 21, 2014: Inhibikase Therapeutics Receives Orphan Drug Designation for treatment of Progressive Multifocal Leukoencephalopathy 26
Apr 25, 2013: Inhibikase Therapeutics To Present Data On IkT-001Pro At 5th International Congress On Polyomaviruses And Human Diseases 26
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29

List of Tables
Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Products under Development by Companies, H2 2017 8
Number of Products by Stage and Target, H2 2017 10
Number of Products by Stage and Mechanism of Action, H2 2017 12
Number of Products by Stage and Molecule Type, H2 2017 14
Progressive Multifocal Leukoencephalopathy - Pipeline by Excision BioTherapeutics Inc, H2 2017 15
Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, H2 2017 15
Progressive Multifocal Leukoencephalopathy - Pipeline by Neuway Pharma GmbH, H2 2017 16
Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, H2 2017 16
Progressive Multifocal Leukoencephalopathy - Dormant Projects, H2 2017 25

List of Figures
Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H2 2017 6
Number of Products under Development by Companies, H2 2017 7
Number of Products by Targets, H2 2017 9
Number of Products by Stage and Targets, H2 2017 9
Number of Products by Mechanism of Actions, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 11
Number of Products by Molecule Types, H2 2017 13
Number of Products by Stage and Molecule Types, H2 2017 13

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *